Sassine leaves Visiomed
Monday, 07 February, 2005
WA biotech Visiomed (ASX:VSG) has replaced retiring CEO Saliba Sassine with William Dolphin, formerly of New Zealand's SpectraNet and patient monitoring equipment company, SonaMed.
Dolphin, who is to take control in April, will be responsible for moving Visiomed's FDA-cleared asthma device, the Funhaler, into commercial production.
The change is one of several to have occurred at CEO level among Australian biotechs this year.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
